#1 Clinical Trials Search in Europe

D-Camphor

This article discusses a clinical trial investigating the use of Aconite Pain Oil, which contains D-Camphor as one of its active ingredients, in cancer patients undergoing chemotherapy. The study aims to prevent and reduce symptoms of chemotherapy-induced polyneuropathy (CIPN) and improve patients’ quality of life. The trial is designed to compare the effectiveness of the Aconite Pain Oil against a placebo in managing CIPN symptoms and potentially reducing the risk of developing severe CIPN.

Table of Contents

What is Aconite Pain Oil?

Aconite Pain Oil, also known as “Aconit Schmerzöl” in German, is a medicinal product being studied for its potential to prevent and reduce symptoms of chemotherapy-induced polyneuropathy (CIPN) in cancer patients[1]. This oil contains several active ingredients, including:

  • D-CAMPHOR: A natural compound derived from the camphor tree, known for its pain-relieving properties
  • Lavender Oil: An essential oil with potential calming and pain-relieving effects
  • Quartz: Used in a highly diluted form according to homeopathic principles
  • Aconitum napellus: A plant-based ingredient prepared using anthroposophic methods

Intended Use

Aconite Pain Oil is being investigated as a treatment for chemotherapy-induced polyneuropathy (CIPN). CIPN is a common side effect of certain chemotherapy drugs, particularly taxanes and platinum derivatives, which can cause nerve damage leading to pain, numbness, and tingling in the hands and feet[1].

How It Works

While the exact mechanism of action is still being studied, Aconite Pain Oil is believed to work through a combination of its active ingredients. The camphor and lavender oil may provide local pain relief and improve circulation, while the homeopathic and anthroposophic components are thought to stimulate the body’s self-healing processes[1].

Clinical Trial Details

A clinical trial is currently underway to evaluate the effectiveness of Aconite Pain Oil in preventing and treating CIPN. The study aims to determine if the oil can[1]:

  • Reduce the risk of developing grade II or higher CIPN by 35% compared to a placebo
  • Improve quality of life for patients undergoing chemotherapy
  • Enhance sleep quality
  • Reduce anxiety and depression associated with CIPN

Potential Benefits

If proven effective, Aconite Pain Oil could offer several benefits for cancer patients undergoing chemotherapy[1]:

  • Prevention or reduction of CIPN symptoms
  • Improved quality of life during and after chemotherapy
  • Better sleep
  • Reduced anxiety and depression
  • Potentially fewer chemotherapy dose reductions or discontinuations due to CIPN

Administration

Aconite Pain Oil is applied externally to the skin. In the clinical trial, patients use a dosing cup to measure the specific volume of oil to be applied. The maximum daily dose is 12 ml, and the treatment period can last up to 7 months[1].

Who Can Use It?

The clinical trial is focusing on adult cancer patients (18 years or older) with solid tumors who are scheduled to receive chemotherapy with taxanes or platinum derivatives for at least 3 months. Patients must have a good overall health status (Karnofsky Index ≥ 70%) and an expected life expectancy of at least 12 months[1].

Precautions

Aconite Pain Oil may not be suitable for everyone. The clinical trial excludes patients with[1]:

  • Previous or current neurotoxic medication use
  • Certain comorbidities like inadequately treated diabetes or renal insufficiency
  • Active infectious diseases
  • Neurological diseases that could interfere with CIPN assessment
  • Known hypersensitivity to camphor or any other ingredients in the oil
  • Pregnancy or breastfeeding

It’s important to note that Aconite Pain Oil is still being studied and is not yet approved for general use. Patients should always consult with their healthcare provider before considering any new treatments for CIPN or other chemotherapy side effects.

Aspect Details
Study Type Prospective, placebo-controlled clinical trial
Main Objective Reduce risk of CIPN grade II and higher by 35% using Aconite Pain Oil compared to placebo
Treatment Aconite Pain Oil containing D-Camphor, applied externally
Dosage Up to 12 ml per day for up to 7 months
Key Inclusion Criteria Age 18+, solid tumors, scheduled for specific chemotherapy, Karnofsky Index ≥70%
Primary Endpoint Time to CIPN of grade II or higher
Secondary Endpoints Quality of life, sleep quality, anxiety and depression levels, patient satisfaction

FAQ

  • What is chemotherapy-induced polyneuropathy (CIPN)? Chemotherapy-induced polyneuropathy (CIPN) is a nerve-related side effect of certain chemotherapy drugs. It can cause symptoms like numbness, tingling, and pain in the hands and feet, affecting a patient's quality of life and potentially limiting their cancer treatment.
  • What is the main goal of this clinical trial? The main goal of this trial is to determine if using Aconite Pain Oil can reduce the risk of developing grade II or higher CIPN by 35% compared to a placebo in cancer patients undergoing chemotherapy.
  • Who can participate in this clinical trial? Participants must be at least 18 years old, have solid tumors, be scheduled for chemotherapy with taxanes or platinum derivatives for at least 3 months, and have a Karnofsky Index of 70% or higher. There are also several exclusion criteria, such as certain pre-existing conditions or use of specific medications.
  • What does the treatment involve? The treatment involves the application of Aconite Pain Oil, which contains D-Camphor and other ingredients, to the skin. Participants will use up to 12 ml per day, measured with a dosing cup, for up to 7 months.
  • How will the effectiveness of the treatment be measured? The effectiveness will be measured through various methods, including the time it takes for CIPN to develop, changes in sensory perception, motor skills, quality of life, sleep quality, and anxiety and depression levels. Researchers will also monitor for any side effects or adverse events.

Ongoing Clinical Trials on D-Camphor

  • Study on Aconite Pain Oil to Prevent and Reduce Symptoms of Chemotherapy-Induced Polyneuropathy in Cancer Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Chemotherapy-induced polyneuropathy (CIPN): A nerve disorder caused by certain chemotherapy drugs, leading to symptoms such as numbness, tingling, and pain in the hands and feet.
  • D-Camphor: An active ingredient in Aconite Pain Oil, derived from the camphor tree, often used for its potential pain-relieving properties.
  • Placebo: A substance with no active medical ingredients, used as a control in clinical trials to compare against the effects of the actual treatment.
  • Karnofsky Index: A scale used to measure a cancer patient's general well-being and ability to perform daily activities, ranging from 0 to 100%.
  • Taxanes: A class of chemotherapy drugs used to treat various types of cancer.
  • Platinum derivatives: Another class of chemotherapy drugs used in cancer treatment.
  • EORTC-QLQ-CIPN20: A questionnaire designed to assess the quality of life in patients experiencing chemotherapy-induced peripheral neuropathy.
  • Anthroposophic: A holistic approach to medicine that combines conventional medical treatment with complementary therapies.
  • Adverse events: Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.

References

  1. http://clinicaltrials.eu/trial/study-on-aconite-pain-oil-to-prevent-and-reduce-symptoms-of-chemotherapy-induced-polyneuropathy-in-cancer-patients/